{
  "question_stem": {
    "en": "A 57-year-old woman comes to the office due to left breast pain associated with fatigue, nausea, and unexplained weight loss. She is referred for mammography, which reveals a 3-Cm dominant mass in the left breast. Biopsy confirms the mass to be adenocarcinoma, and subsequent studies find that the tumor is estrogen receptor-positive and human epidermal growth factor receptor 2- (HER2) negative. The patient experienced menopause at age 52, and her past medical history is otherwise unremarkable. Anastrozole treatment is initiated and leads to a substantial decrease in the size of the primary tumor. ",
    "zh": "一名57岁女性因左乳疼痛伴疲劳、恶心和不明原因的体重减轻前来就诊。她被转诊进行乳房X线摄影检查，结果显示左乳有一个3厘米的优势肿块。活检证实该肿块为腺癌，后续研究发现该肿瘤雌激素受体阳性，人表皮生长因子受体2（HER2）阴性。该患者在52岁时经历了绝经，其既往病史无其他特殊情况。开始使用阿那曲唑治疗，导致原发肿瘤大小显着减小。"
  },
  "question": {
    "en": "Which of the following is the best explanation for the therapeutic effect of this agent?",
    "zh": "以下哪项是该药物治疗作用的最佳解释？"
  },
  "options": {
    "A": {
      "en": "Decreased androgen aromatization",
      "zh": "减少雄激素芳香化"
    },
    "B": {
      "en": "Decreased androgen synthesis",
      "zh": "减少雄激素合成"
    },
    "C": {
      "en": "Decreased follicular cell stimulation",
      "zh": "减少卵泡细胞刺激"
    },
    "D": {
      "en": "Impaired ligand-receptor interaction",
      "zh": "受体-配体相互作用受损"
    },
    "E": {
      "en": "Impaired second-messenger action",
      "zh": "第二信使作用受损"
    }
  },
  "correct_answer": "A",
  "explanation": {
    "en": "Estrogens are synthesized primarily by the aromatization of androgens. Aromatase {{exhibit_1}} belongs to the P450 superfamily and is highly expressed in ovarian tissue (in which expression is gonadotropin dependent). Aromatase is also expressed in the adrenal cortex, subcutaneous fat, and breast. In the postmenopausal state, follicular atresia leads to reduced numbers of granulosa cells and decreased ovarian estrogen synthesis. However, the ovaries and adrenal glands continue to produce androgens in significant quantities, and extraovarian aromatase maintains a low level of estrogen in the peripheral circulation.\n\nEstrogen is the main hormone driving the growth and development of estrogen receptor (ER)-positive malignant breast tumors. Aromatase inhibitors (eg, anastrozole, letrozole, exemestane) reduce the synthesis of estrogen from androgens, suppressing estrogen levels in postmenopausal women and slowing progression of ER-positive tumors. They are less effective as monotherapy in premenopausal women, as ovarian aromatase is upregulated substantially in response to gonadotropins.\n\n(Choice B) Although inhibition of androgen synthesis could theoretically decrease estrogen synthesis, most androgen synthesis inhibitors (eg, ketoconazole) are nonspecific and suppress other pathways of steroidogenesis (eg, cortisol, mineralocorticoid).\n\n(Choice C) Pulsatile stimulation of the pituitary by gonadotropin-releasing hormone (GnRH) increases secretion of LH and FSH. However, continuous GnRH stimulation by long-acting GnRH analogs (eg, goserelin) suppresses LH and FSH release, decreasing production of estrogens in the ovarian follicle. These agents are useful for ovarian suppression in premenopausal women with ER-positive breast cancer.\n\n(Choice D) Tamoxifen acts as either an antagonist or a partial agonist of the estrogen receptor, depending on the tissue. In breast tissue, tamoxifen antagonizes the estrogen receptor and can be used as adjuvant therapy for ER-positive breast cancer.\n\n(Choice E) Many breast cancers overexpress epidermal growth factor receptor 2 (HER2). Trastuzumab is a monoclonal antibody against HER2 that is used in patients with HER2-positive tumors. It inhibits MAPK and PI3K/Akt signaling pathways, increases degradation of HER2, and facilitates antibody-mediated destruction of tumor cells.\n\nEducational objective:\nEstrogen is the main hormone responsible for the growth and development of estrogen receptor (ER)-positive breast tumors. Aromatase inhibitors (eg, anastrozole, letrozole, exemestane) decrease the synthesis of estrogen from androgens, suppressing estrogen levels and slowing progression of ER-positive tumors.",
    "zh": "雌激素主要通过雄激素的芳香化合成。芳香化酶 {{exhibit_1}} 属于P450超家族，在卵巢组织中高度表达（其表达依赖于促性腺激素）。芳香化酶也表达于肾上腺皮质、皮下脂肪和乳房。在绝经后状态下，卵泡闭锁导致颗粒细胞数量减少和卵巢雌激素合成减少。然而，卵巢和肾上腺继续产生大量雄激素，卵巢外芳香化酶维持外周循环中低水平的雌激素。\n\n雌激素是驱动雌激素受体 (ER) 阳性恶性乳腺肿瘤生长和发育的主要激素。芳香化酶抑制剂（例如，阿那曲唑、来曲唑、依西美坦）减少雄激素合成雌激素，从而抑制绝经后妇女的雌激素水平并减缓ER阳性肿瘤的进展。作为单药治疗，它们在绝经前妇女中效果较差，因为卵巢芳香化酶对促性腺激素的反应显着上调。\n\n(选项 B) 虽然抑制雄激素合成在理论上可以减少雌激素合成，但大多数雄激素合成抑制剂（例如，酮康唑）是非特异性的，并抑制类固醇生成的其他途径（例如，皮质醇、盐皮质激素）。\n\n(选项 C) 促性腺激素释放激素 (GnRH) 对垂体的脉冲刺激会增加 LH 和 FSH 的分泌。然而，长效 GnRH 类似物（例如戈舍瑞林）的持续 GnRH 刺激会抑制 LH 和 FSH 的释放，从而减少卵巢卵泡中雌激素的产生。这些药物可用于ER阳性乳腺癌绝经前妇女的卵巢抑制。\n\n(选项 D) 他莫昔芬的作用是雌激素受体的拮抗剂或部分激动剂，具体取决于组织。在乳房组织中，他莫昔芬拮抗雌激素受体，可用作 ER 阳性乳腺癌的辅助治疗。\n\n(选项 E) 许多乳腺癌过度表达人表皮生长因子受体 2 (HER2)。曲妥珠单抗是一种针对 HER2 的单克隆抗体，用于HER2阳性肿瘤患者。它抑制 MAPK 和 PI3K/Akt 信号通路，增加HER2的降解，并促进抗体介导的肿瘤细胞破坏。\n\n教育目标：\n雌激素是导致雌激素受体 (ER) 阳性乳腺肿瘤生长和发育的主要激素。芳香化酶抑制剂（例如，阿那曲唑、来曲唑、依西美坦）减少雄激素合成雌激素，从而抑制雌激素水平并减缓ER阳性肿瘤的进展。"
  },
  "summary": {
    "en": "This question tests knowledge of aromatase inhibitors and their mechanism of action in treating estrogen receptor-positive breast cancer, particularly in postmenopausal women. It requires understanding of estrogen synthesis pathways and the role of aromatase in converting androgens to estrogens.\n\nTo solve this question, recognize that anastrozole is an aromatase inhibitor. Recall that aromatase inhibitors reduce estrogen production by blocking the conversion of androgens to estrogens, thereby slowing the growth of estrogen-dependent tumors in postmenopausal women.",
    "zh": "本题考察了关于芳香化酶抑制剂及其在治疗雌激素受体阳性乳腺癌（尤其是在绝经后妇女中）中的作用机制的知识。它需要理解雌激素合成途径以及芳香化酶在将雄激素转化为雌激素中的作用。\n\n要解决这个问题，需要认识到阿那曲唑是一种芳香化酶抑制剂。回想一下，芳香化酶抑制剂通过阻断雄激素转化为雌激素来减少雌激素的产生，从而减缓绝经后妇女中雌激素依赖性肿瘤的生长。"
  },
  "tags": "Aromatase inhibitors; Estrogen receptor-positive breast cancer; Postmenopausal women; Estrogen synthesis; Androgen aromatization; Oncology; Endocrinology",
  "category": "Endo",
  "question_id": "584",
  "has_exhibits": true,
  "exhibit_count": 1,
  "exhibit_files": [
    "image1.jpg"
  ],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\Endo 23\\584",
  "extracted_at": "2025-11-05T14:08:30.691008",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 1,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T17:41:50.187377",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}